Nortran Signs Licensing Agreement With Astrazeneca

Under the terms of the agreement, Nortran Pharmaceuticals Inc. will grant AstraZeneca PLC an exclusive worldwide license to develop and market a novel antiarrhythmic drug candidate in exchange for upfront, milestone, and royalty payments. AstraZeneca will pay for all development and marketing costs. The agreement covers a single Nortran antiarrhythmic drug candidate, allowing Nortran the Read more about Nortran Signs Licensing Agreement With Astrazeneca[…]

Cell Therapeutics Receives FDA Approval For Trisenox

Cell Therapeutics, Inc. (cti) TRISENOX (arsenic trioxide) injection was approved today by the U.S. FDA to treat patients with a severe form of leukaemia whose disease has recurred or who have failed to respond to standard therapy. “For patients with APL whose disease has recurred following initial treatment, the use of salvage therapy is highly Read more about Cell Therapeutics Receives FDA Approval For Trisenox[…]

Generex Receives License From Presspart

Generex Biotechnology Corporation and Presspart Group Limited have entered into a commercial supply agreement for a key component of Generex’s RapidMist device. Under the agreement, Generex will purchase its requirements of pharmaceutical aerosol cans used for the buccal delivery of insulin from UK-based Presspart. Presspart has granted an exclusive license to Generex for the use Read more about Generex Receives License From Presspart[…]

Bio-Technology General Signs Deal For BioTechnology

Bio-Technology General Corp. has entered into an exclusive agreement with DePuy Orthopaedics Inc. (DePuy), for BioHy, BTG’s proprietary high molecular weight sodium hyaluronate product, for the treatment of pain associated with osteoarthritis of the knee. The agreement grants DePuy exclusive marketing rights to BioHy in all countries worldwide except Japan and Israel. Clinical efforts, where Read more about Bio-Technology General Signs Deal For BioTechnology[…]

Supergen And Stehlin Foundation Expand Research Agreement

SuperGen Inc. has extended its research agreement with the Stehlin Foundation for Cancer Research to eight years. As part of this agreement, SuperGen also secured the global rights to other camptothecins and additional anticancer compounds. One of these compounds has already demonstrated marked antitumor activity and is expected to have a very favorable safety profile. Read more about Supergen And Stehlin Foundation Expand Research Agreement[…]

Orion Pharma Gains Rights To Nestorone In Transdermal Gels

Orion Pharma has entered into a licensing agreement with the Population Council, an international, nonprofit U.S.-based organization, providing Orion Pharma worldwide exclusive rights to develop, manufacture, market, sell, and sublicense the synthetic progestin, Nestorone, for hormone replacement therapy (HRT) in transdermal dosage forms other than the patch. Nestorone is a new chemical entity that is Read more about Orion Pharma Gains Rights To Nestorone In Transdermal Gels[…]

SmithKline Beecham To Extend Agreement With NPS Pharmaceuticals

NPS Pharmaceuticals, Inc has announced that SmithKline Beecham (SB) will continue funding work at NPS under an existing collaborative research and license agreement begun in 1993. NPS and SB are engaged in research efforts to find novel therapies for osteoporosis. Under the terms of the agreement, SB has also purchased shares of NPS stock. The Read more about SmithKline Beecham To Extend Agreement With NPS Pharmaceuticals[…]

Merck Completes Acquisition Of Sibia

Merck & Co., Inc. has announced that its wholly owned subsidiary, MC Subsidiary Corp., has acquired SIBIA Neurosciences, Inc. by completing its previously announced merger with SIBIA. MC Subsidiary Corp. completed in September a tender offer in which it purchased approximately 69 percent of the outstanding common stock of SIBIA for $8.50 per share. As Read more about Merck Completes Acquisition Of Sibia[…]

Antares Pharma NPMG Alliance For Topical Anesthetic

Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a Read more about Antares Pharma NPMG Alliance For Topical Anesthetic[…]

Genvec And Nih Expand Hiv Vaccine Manufacturing Contract

The Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has expanded its multi-year subcontract with GenVec, Inc. This latest expansion of the subcontract increases the total potential funding from approximately $16 million to approximately $28 million. GenVec will manufacture a HIV vaccine Read more about Genvec And Nih Expand Hiv Vaccine Manufacturing Contract[…]